{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:32:19Z","timestamp":1790199139260,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human pleural mesothelioma is an incurable and chemoresistant cancer. Using a nude mouse xenograft model of human pleural mesothelioma, we show that RAPTA-T, a compound undergoing preclinical evaluation, enhances tumor vascular function by decreasing blood vessel tortuosity and dilation, while increasing the coverage of endothelial cells by pericytes and vessel perfusion within tumors. This in turn significantly reduces the interstitial fluid pressure and increases oxygenation in the tumor. Consequently, RAPTA-T pre-treatment followed by the application of cisplatin or liposomal cisplatin (Lipoplatin) leads to increased levels of the cytotoxin in the tumor and enhanced mesothelioma growth inhibition. We demonstrate that the vascular changes induced by RAPTA-T are related, in part, to the inhibition of poly-(ADP-ribose) polymerase 1 (PARP-1) which is associated to tumor vascular stabilization. These findings suggest novel therapeutic implications for RAPTA-T to create conditions for superior drug uptake and efficacy of approved cytotoxic anti-cancer drugs in malignant pleural mesothelioma and potentially other chemoresistant tumors.<\/jats:p>","DOI":"10.1038\/s41598-018-28589-2","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T11:25:29Z","timestamp":1530530729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Tina","family":"Riedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Liaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Beat","family":"Ris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Y.","family":"Perentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"28589_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","volume":"9","author":"BC Cho","year":"2014","unstructured":"Cho, B. C. et al. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the \u201cSMART\u201d approach for resectable malignant pleural mesothelioma. J Thorac Oncol 9, 397\u2013402, https:\/\/doi.org\/10.1097\/JTO.0000000000000078 (2014).","journal-title":"J Thorac Oncol"},{"key":"28589_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","volume":"16","author":"RA Stahel","year":"2015","unstructured":"Stahel, R. A. et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16, 1651\u20131658, https:\/\/doi.org\/10.1016\/S1470-2045(15)00208-9 (2015).","journal-title":"Lancet Oncol"},{"key":"28589_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","volume":"73","author":"RJ Kelly","year":"2011","unstructured":"Kelly, R. J., Sharon, E. & Hassan, R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73, 256\u2013263, https:\/\/doi.org\/10.1016\/j.lungcan.2011.04.014 (2011).","journal-title":"Lung Cancer"},{"key":"28589_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3978\/j.issn.2225-319X.2012.11.12","volume":"1","author":"W Weder","year":"2012","unstructured":"Weder, W. & Opitz, I. Multimodality therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 1, 502\u2013507, https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2012.11.12 (2012).","journal-title":"Ann Cardiothorac Surg"},{"key":"28589_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605\u2013622, https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006 (2014).","journal-title":"Cancer Cell"},{"key":"28589_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4, 806\u2013813, https:\/\/doi.org\/10.1038\/nrc1456 (2004).","journal-title":"Nat Rev Cancer"},{"key":"28589_CR7","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","volume":"64","author":"RT Tong","year":"2004","unstructured":"Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731\u20133736, https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0074 (2004).","journal-title":"Cancer Res"},{"key":"28589_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2004.10.011","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553\u2013563, https:\/\/doi.org\/10.1016\/j.ccr.2004.10.011 (2004).","journal-title":"Cancer Cell"},{"key":"28589_CR9","doi-asserted-by":"publisher","first-page":"19059","DOI":"10.1073\/pnas.1318022110","volume":"110","author":"TT Batchelor","year":"2013","unstructured":"Batchelor, T. T. et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110, 19059\u201319064, https:\/\/doi.org\/10.1073\/pnas.1318022110 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"28589_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1634\/theoncologist.2010-0030","volume":"15","author":"CG Willett","year":"2010","unstructured":"Willett, C. G. et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I\/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 15, 845\u2013851, https:\/\/doi.org\/10.1634\/theoncologist.2010-0030 (2010).","journal-title":"Oncologist"},{"key":"28589_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83\u201395, https:\/\/doi.org\/10.1016\/j.ccr.2006.11.021 (2007).","journal-title":"Cancer Cell"},{"key":"28589_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2014.04.010","author":"JY Perentes","year":"2014","unstructured":"Perentes, J. Y. et al. Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. Transl Oncol. https:\/\/doi.org\/10.1016\/j.tranon.2014.04.010 (2014).","journal-title":"Transl Oncol"},{"key":"28589_CR13","first-page":"8126","volume":"63","author":"JW Snyder","year":"2003","unstructured":"Snyder, J. W., Greco, W. R., Bellnier, D. A., Vaughan, L. & Henderson, B. W. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 63, 8126\u20138131 (2003).","journal-title":"Cancer Res"},{"key":"28589_CR14","doi-asserted-by":"publisher","first-page":"R1161","DOI":"10.1016\/j.cub.2016.09.043","volume":"26","author":"PP Wong","year":"2016","unstructured":"Wong, P. P., Bodrug, N. & Hodivala-Dilke, K. M. Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment. Curr Biol 26, R1161\u2013R1166, https:\/\/doi.org\/10.1016\/j.cub.2016.09.043 (2016).","journal-title":"Curr Biol"},{"key":"28589_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jinorgbio.2011.09.030","volume":"106","author":"A Bergamo","year":"2012","unstructured":"Bergamo, A., Gaiddon, C., Schellens, J. H., Beijnen, J. H. & Sava, G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem 106, 90\u201399, https:\/\/doi.org\/10.1016\/j.jinorgbio.2011.09.030 (2012).","journal-title":"J Inorg Biochem"},{"key":"28589_CR16","first-page":"1281","volume":"33","author":"A Bergamo","year":"2008","unstructured":"Bergamo, A., Masi, A., Dyson, P. J. & Sava, G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol 33, 1281\u20131289 (2008).","journal-title":"Int J Oncol"},{"key":"28589_CR17","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1021\/jm050015d","volume":"48","author":"C Scolaro","year":"2005","unstructured":"Scolaro, C. et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 48, 4161\u20134171, https:\/\/doi.org\/10.1021\/jm050015d (2005).","journal-title":"J Med Chem"},{"key":"28589_CR18","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1021\/jm2002074","volume":"54","author":"P Nowak-Sliwinska","year":"2011","unstructured":"Nowak-Sliwinska, P. et al. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem 54, 3895\u20133902, https:\/\/doi.org\/10.1021\/jm2002074 (2011).","journal-title":"J Med Chem"},{"key":"28589_CR19","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1021\/jm2000135","volume":"54","author":"F Mendes","year":"2011","unstructured":"Mendes, F. et al. Metal-based inhibition of poly(ADP-ribose) polymerase\u2013the guardian angel of DNA. J Med Chem 54, 2196\u20132206, https:\/\/doi.org\/10.1021\/jm2000135 (2011).","journal-title":"J Med Chem"},{"key":"28589_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fonc.2013.00290","volume":"3","author":"AN Weaver","year":"2013","unstructured":"Weaver, A. N. & Yang, E. S. Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. Front Oncol 3, 290, https:\/\/doi.org\/10.3389\/fonc.2013.00290 (2013).","journal-title":"Front Oncol"},{"key":"28589_CR21","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.3892\/ol.2016.5226","volume":"12","author":"W Wei","year":"2016","unstructured":"Wei, W., Li, Y., Lv, S., Zhang, C. & Tian, Y. PARP-1 may be involved in angiogenesis in epithelial ovarian cancer. Oncol Lett 12, 4561\u20134567, https:\/\/doi.org\/10.3892\/ol.2016.5226 (2016).","journal-title":"Oncol Lett"},{"key":"28589_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145\u2013147, https:\/\/doi.org\/10.1038\/nm988 (2004).","journal-title":"Nat Med"},{"key":"28589_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/hc0102.101437","volume":"105","author":"A Abramsson","year":"2002","unstructured":"Abramsson, A. et al. Analysis of mural cell recruitment to tumor vessels. Circulation 105, 112\u2013117 (2002).","journal-title":"Circulation"},{"key":"28589_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","volume":"160","author":"S Morikawa","year":"2002","unstructured":"Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160, 985\u20131000, https:\/\/doi.org\/10.1016\/S0002-9440(10)64920-6 (2002).","journal-title":"Am J Pathol"},{"key":"28589_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.bbrc.2006.09.160","volume":"350","author":"M Rajesh","year":"2006","unstructured":"Rajesh, M. et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun 350, 1056\u20131062, https:\/\/doi.org\/10.1016\/j.bbrc.2006.09.160 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"28589_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2217\/imt.12.112","volume":"4","author":"S Kakarla","year":"2012","unstructured":"Kakarla, S., Song, X. T. & Gottschalk, S. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4, 1129\u20131138, https:\/\/doi.org\/10.2217\/imt.12.112 (2012).","journal-title":"Immunotherapy"},{"key":"28589_CR27","first-page":"2497","volume":"60","author":"PA Netti","year":"2000","unstructured":"Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60, 2497\u20132503 (2000).","journal-title":"Cancer Res"},{"key":"28589_CR28","first-page":"1310","volume":"33","author":"RC DeConti","year":"1973","unstructured":"DeConti, R. C., Toftness, B. R., Lange, R. C. & Creasey, W. A. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33, 1310\u20131315 (1973).","journal-title":"Cancer Res"},{"key":"28589_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/lsm.22329","volume":"47","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Fluence plays a critical role on the subsequent distribution of chemotherapy and tumor growth delay in murine mesothelioma xenografts pre-treated by photodynamic therapy. Lasers Surg Med 47, 323\u2013330, https:\/\/doi.org\/10.1002\/lsm.22329 (2015).","journal-title":"Lasers Surg Med"},{"key":"28589_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/cc6118","volume":"11","author":"D De Backer","year":"2007","unstructured":"De Backer, D. et al. How to evaluate the microcirculation: report of a round table conference. Crit Care 11, R101, https:\/\/doi.org\/10.1186\/cc6118 (2007).","journal-title":"Crit Care"},{"key":"28589_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0026-2862(77)90138-8","volume":"14","author":"HO Fadnes","year":"1977","unstructured":"Fadnes, H. O., Reed, R. K. & Aukland, K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14, 27\u201336 (1977).","journal-title":"Microvasc Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28589-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:19:10Z","timestamp":1671607150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28589"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28589-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,6]]},"assertion":[{"value":"29 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10263"}}